Considering the efficacy of anti-TNFα agents in the treatment of RA [99], the fact that TRPA1 appears to be downstream of TNFα in the pathology of arthritis positions it as a potentially important drug target. This evidence concerns the gene TRPA1 and arthritic joint disease.